JP2008540499A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540499A5 JP2008540499A5 JP2008510642A JP2008510642A JP2008540499A5 JP 2008540499 A5 JP2008540499 A5 JP 2008540499A5 JP 2008510642 A JP2008510642 A JP 2008510642A JP 2008510642 A JP2008510642 A JP 2008510642A JP 2008540499 A5 JP2008540499 A5 JP 2008540499A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cyclodextrin
- hdac inhibitor
- arginine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 49
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 29
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 29
- 229920000858 Cyclodextrin Polymers 0.000 claims 26
- 239000004475 Arginine Substances 0.000 claims 18
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 18
- 235000009697 arginine Nutrition 0.000 claims 18
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 15
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 229960003194 meglumine Drugs 0.000 claims 12
- 125000004450 alkenylene group Chemical group 0.000 claims 9
- 125000002947 alkylene group Chemical group 0.000 claims 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 6
- 239000001116 FEMA 4028 Substances 0.000 claims 6
- 229960004853 betadex Drugs 0.000 claims 6
- 125000005549 heteroarylene group Chemical group 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims 5
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims 5
- 238000001802 infusion Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 102000003964 Histone deacetylase Human genes 0.000 claims 3
- 108090000353 Histone deacetylase Proteins 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 150000002170 ethers Chemical class 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 239000002504 physiological saline solution Substances 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 2
- 229930064664 L-arginine Natural products 0.000 claims 2
- 235000014852 L-arginine Nutrition 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000005488 carboaryl group Chemical group 0.000 claims 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000002510 pyrogen Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1
- 239000008215 water for injection Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68121505P | 2005-05-13 | 2005-05-13 | |
| US68123405P | 2005-05-13 | 2005-05-13 | |
| US60/681,215 | 2005-05-13 | ||
| US60/681,234 | 2005-05-13 | ||
| PCT/GB2006/001737 WO2006120456A1 (en) | 2005-05-13 | 2006-05-11 | Pharmaceutical formulations of hdac inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012128900A Division JP5567068B2 (ja) | 2005-05-13 | 2012-06-06 | Ｈｄａｃ阻害剤の医薬製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008540499A JP2008540499A (ja) | 2008-11-20 |
| JP2008540499A5 true JP2008540499A5 (cg-RX-API-DMAC7.html) | 2009-06-25 |
| JP5108750B2 JP5108750B2 (ja) | 2012-12-26 |
Family
ID=36617353
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008510642A Active JP5108750B2 (ja) | 2005-05-13 | 2006-05-11 | Ｈｄａｃ阻害剤の医薬製剤 |
| JP2012128900A Expired - Fee Related JP5567068B2 (ja) | 2005-05-13 | 2012-06-06 | Ｈｄａｃ阻害剤の医薬製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012128900A Expired - Fee Related JP5567068B2 (ja) | 2005-05-13 | 2012-06-06 | Ｈｄａｃ阻害剤の医薬製剤 |
Country Status (26)
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2522397A1 (en) | 2005-02-03 | 2012-11-14 | TopoTarget UK Limited | Combination therapies using HDAC inhibitors |
| ZA200710313B (en) | 2005-05-13 | 2009-05-27 | Topotarget Uk Ltd | Pharmaceutical formulations of HDAC inhibitors |
| EP2361619A1 (en) | 2005-11-10 | 2011-08-31 | TopoTarget UK Limited | Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer |
| ITRM20070038A1 (it) * | 2007-01-26 | 2008-07-27 | Uni Degli Studi Di Roma La Sapienza | Forme solubili di complessi di inclusione di inibitori dell istone deacetilasi e ciclodestrine loro processi di preparazione e impieghi in campo farmaceutico |
| EP2192904B1 (en) * | 2007-08-27 | 2016-08-17 | Auxagen, Inc. | METHODS FOR INHIBITING TGF-beta |
| US8642809B2 (en) * | 2007-09-25 | 2014-02-04 | Topotarget Uk Ltd. | Methods of synthesis of certain hydroxamic acid compounds |
| EP2262493B1 (en) * | 2008-03-07 | 2015-02-25 | Topotarget A/S | Methods of treatment employing prolonged continuous infusion of belinostat |
| EP2341913B1 (en) * | 2008-09-16 | 2014-11-19 | Saint Louis University | Method of enhancing tgf-beta signalling |
| EP2340242A4 (en) | 2008-10-22 | 2012-04-04 | Acucela Inc | COMPOUNDS FOR THE TREATMENT OF EYE DISEASES AND DRESSES |
| GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| WO2011064663A1 (en) | 2009-11-25 | 2011-06-03 | Festuccia, Claudio | Combination treatment employing belinostat and bicalutamide |
| CN103442715A (zh) | 2011-03-21 | 2013-12-11 | 瓦尔库里亚公司 | 包括hdac抑制剂以及类固醇的药用组合物及其用途 |
| ME03088B (me) * | 2011-09-18 | 2019-01-20 | Euro Celtique Sa | Postupak za proizvodnju stabilnog, injektabilnog rastvora noradrenalina niske koncentracije |
| CN104136410A (zh) * | 2011-12-29 | 2014-11-05 | 药品循环公司 | 作为组蛋白脱乙酰酶8抑制剂的肉桂酸羟基酰胺 |
| TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
| RU2715236C2 (ru) | 2014-03-26 | 2020-02-26 | Астекс Терапьютикс Лтд | Комбинации |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| MX2016016311A (es) | 2014-06-12 | 2017-10-12 | Univ Notre Dame Du Lac | Composición y método para el tratamiento de enfermedades neurológicas y lesión cerebral. |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| EA201792028A1 (ru) | 2015-03-13 | 2018-04-30 | Форма Терапьютикс, Инк. | Альфа-цинамидные соединения и композиции как ингибиторы hdac8 |
| WO2016205203A1 (en) | 2015-06-16 | 2016-12-22 | Spectrum Pharmaceuticals, Inc. | Combination therapy using belinostat and pralatrexate to treat lymphoma |
| CN105481736A (zh) * | 2015-12-28 | 2016-04-13 | 山东大学 | 一种含有苯甘氨酸的肉桂酰胺类组蛋白去乙酰化酶抑制剂及其制备方法和应用 |
| WO2017144543A1 (en) | 2016-02-22 | 2017-08-31 | Onxeo | Combination therapies comprising immuno-oncology agents and belinostat |
| PT3347055T (pt) | 2016-03-31 | 2019-09-13 | Midatech Ltd | Aduto de ciclodextrina-panobinostat |
| US20190224146A1 (en) * | 2016-07-08 | 2019-07-25 | Ranedis Pharmaceuticals, Llc | Compositions and methods of treating and/or preventing lysosomal storage diseases and other monogenetic metabolic diseases |
| CN107638571B (zh) | 2016-07-15 | 2021-07-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种特考韦瑞口服药物组合物及其制备方法 |
| CN107625967B (zh) * | 2016-07-15 | 2021-07-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种特考韦瑞注射用药物组合物及其制备方法 |
| WO2018029699A1 (en) * | 2016-08-11 | 2018-02-15 | Msn Research & Development Center | Solid state forms of (2e)-n-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide and process for preparation thereof |
| US11266631B2 (en) | 2016-10-11 | 2022-03-08 | Purdue Pharmaceutical Products L.P. | Hodgkin lymphoma therapy |
| CN106389359B (zh) * | 2016-11-30 | 2019-07-26 | 瑞阳制药有限公司 | 供注射用的贝利司他药物组合物及其制备方法 |
| CN108210501B (zh) * | 2016-12-14 | 2019-03-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种磺酰脲类药物的注射用药物组合物及其制备方法 |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| SI3644970T1 (sl) * | 2017-06-30 | 2022-05-31 | Acrotech Biopharma Llc | Nove oralne formulacije belinostata |
| WO2019067145A1 (en) * | 2017-08-28 | 2019-04-04 | Asdera Llc | USE OF CYCLODEXTRINS IN DISEASES AND DISORDERS INVOLVING PHOSPHOLIPID DISRUPTION |
| EP3461488A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dbait molecule and a hdac inhibitor for treating cancer |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| CA3076821A1 (en) * | 2017-09-28 | 2019-04-04 | Asdera Llc | Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation |
| KR20200046143A (ko) | 2018-10-15 | 2020-05-07 | 주식회사 아이엠알 | 보안기능이 있는 Pluggable 형태의 IoT 센서 노드 및 게이트웨이 구성 방법 |
| KR20210105380A (ko) | 2018-12-18 | 2021-08-26 | 먼디파머 인터내셔널 코포레이션 리미티드 | 다발성 골수종을 치료하기 위한 화합물 |
| WO2021071809A1 (en) * | 2019-10-07 | 2021-04-15 | Viracta Therapeutics, Inc. | Dosages for hdac treatment with reduced side effects |
| JP7495340B2 (ja) * | 2020-12-16 | 2024-06-04 | 株式会社ファンケル | カルノシン酸含有固体組成物及びカルノシン酸の溶出促進方法 |
| CN113413389B (zh) * | 2021-07-19 | 2024-03-15 | 成都赜灵生物医药科技有限公司 | 一种组蛋白去乙酰化酶抑制剂的制剂及其制备方法和用途 |
| EP4405680A1 (en) | 2021-09-20 | 2024-07-31 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
| CN115737549A (zh) * | 2022-11-24 | 2023-03-07 | 北京鑫开元医药科技有限公司 | 一种具有hdac抑制活性的注射液及其制备方法和用途 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025257176A1 (en) | 2024-06-13 | 2025-12-18 | Ideogen A.G. | Combination therapy for treating cancer such as lymphoma |
| WO2025257171A1 (en) | 2024-06-13 | 2025-12-18 | Ideogen A.G. | Combination therapy for treating cancer such as lymphoma |
| WO2025257173A1 (en) | 2024-06-13 | 2025-12-18 | Ideogen A.G. | Combination therapy for treating cancer such as lymphoma |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH647412A5 (de) | 1980-03-25 | 1985-01-31 | Hoffmann La Roche | Pharmazeutische praeparate. |
| US4642316A (en) | 1985-05-20 | 1987-02-10 | Warner-Lambert Company | Parenteral phenytoin preparations |
| DE4010536A1 (de) * | 1990-04-02 | 1991-10-10 | Boehringer Mannheim Gmbh | Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure |
| US6071923A (en) | 1994-09-16 | 2000-06-06 | Bar-Ilan University | Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases |
| US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
| RU2164914C2 (ru) | 1995-11-13 | 2001-04-10 | Хехст Акциенгезелльшафт | ЦИКЛИЧЕСКИЕ И ГЕТЕРОЦИКЛИЧЕСКИЕ N-ЗАМЕЩЕННЫЕ α-ИМИНОГИДРОКСАМОВЫЕ И КАРБОНОВЫЕ КИСЛОТЫ |
| KR100466955B1 (ko) * | 1996-02-26 | 2005-06-10 | 에자이 가부시키가이샤 | 항종양제함유조성물 |
| EP0827742A1 (en) | 1996-09-04 | 1998-03-11 | Vrije Universiteit Brussel | Use of histone deacetylase inhibitors for treating fribosis or cirrhosis |
| EP1123309A2 (en) | 1998-10-13 | 2001-08-16 | Fujisawa Pharmaceutical Co., Ltd. | Cyclic tetrapeptides and their use as histone deacetylase inhibitor |
| JP2000212088A (ja) * | 1999-01-27 | 2000-08-02 | Kobayashi Kako Kk | 難溶性抗ウイルス剤の水溶液 |
| US20070148228A1 (en) | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
| WO2000064946A2 (en) | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| EP1748046A3 (en) | 1999-11-23 | 2007-08-22 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| AU2001290131B2 (en) | 2000-09-29 | 2007-11-15 | Topotarget Uk Limited | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
| GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
| DE60115279T2 (de) | 2000-09-29 | 2006-12-28 | Topotarget Uk Ltd., Abingdon | Carbaminsäurederivate enthaltend eine amidgruppe als hdac-inhibitoren |
| JPWO2002074298A1 (ja) | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Ｉｌ−６産生阻害剤 |
| AR035455A1 (es) * | 2001-04-23 | 2004-05-26 | Hoffmann La Roche | Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos |
| EP1390491B1 (en) | 2001-05-02 | 2008-07-16 | The Regents of the University of California | Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors |
| NZ541950A (en) | 2001-08-09 | 2007-02-23 | Ono Pharmaceutical Co | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
| US8470783B2 (en) | 2001-08-21 | 2013-06-25 | Astellas Pharma Inc. | Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| EP1293205A1 (en) | 2001-09-18 | 2003-03-19 | G2M Cancer Drugs AG | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |
| YU75003A (sh) * | 2002-01-11 | 2006-08-17 | Matthias Rath | Nutriciona farmaceutska formulacija koja uključuje polifenole i upotreba u tretmanu kancera |
| EP1472216A2 (en) | 2002-02-07 | 2004-11-03 | Axys Pharmaceuticals | Novel bicyclic hydroxamates as inhibitors of histone deacetylase |
| JP2005525345A (ja) | 2002-02-15 | 2005-08-25 | スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ | Ｔｒｘ媒介性疾患を処置する方法 |
| US20050288227A1 (en) | 2002-02-15 | 2005-12-29 | Marks Paul A | Use of thioredoxin measurements for diagnostics and treatments |
| CA2632078C (en) | 2002-03-04 | 2012-08-14 | Sloan-Kettering Institute For Cancer Research | Methods of inducing terminal differentiation |
| US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| US20070060614A1 (en) | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
| US20040132825A1 (en) | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| ATE425152T1 (de) | 2002-03-13 | 2009-03-15 | Janssen Pharmaceutica Nv | Aminocarbonylderivate als histone-deacetylase- inhibitoren |
| NZ536116A (en) | 2002-04-03 | 2007-01-26 | Topotarget Uk Ltd | Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors |
| TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| US7495022B2 (en) | 2002-04-11 | 2009-02-24 | Sk Chemicals Co., Ltd. | α,β-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors |
| MXPA04010199A (es) * | 2002-04-15 | 2005-07-05 | Sloan Kettering Inst Cancer | Terapia en combinacion para el tratamiento de cancer. |
| US8883148B2 (en) * | 2002-04-26 | 2014-11-11 | Asan Laboratories Company (Cayman), Limited | Prevention of joint destruction |
| GB0209715D0 (en) | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| JP2003321364A (ja) * | 2002-05-07 | 2003-11-11 | Eisai Co Ltd | シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物 |
| DE10233412A1 (de) | 2002-07-23 | 2004-02-12 | 4Sc Ag | Neue Verbindungen als Histondeacetylase-Inhibitoren |
| BR0313371A (pt) | 2002-08-02 | 2005-07-05 | Argenta Discovery Ltd | Composto, uso de um composto e método de tratamento de doença |
| GB0226370D0 (en) | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
| US20080004311A1 (en) | 2002-11-12 | 2008-01-03 | Alcon, Inc. | Histone deacetylase inhibitors for treating degenerative diseases of the eye |
| ITMI20030025A1 (it) | 2003-01-10 | 2004-07-11 | Italfarmaco Spa | Derivati dell'acido idrossammico ad attivita' antinfiammatoria. |
| US7135493B2 (en) | 2003-01-13 | 2006-11-14 | Astellas Pharma Inc. | HDAC inhibitor |
| US20050222013A1 (en) | 2003-01-16 | 2005-10-06 | Georgetown University | Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy |
| TW200424174A (en) | 2003-02-06 | 2004-11-16 | Hoffmann La Roche | New TP diamide |
| AU2003900608A0 (en) | 2003-02-11 | 2003-02-27 | Fujisawa Pharmaceutical Co., Ltd. | Hdac inhibitor |
| US7244751B2 (en) | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
| JP2006518219A (ja) | 2003-02-18 | 2006-08-10 | マックスサイト インコーポレーティッド | 電気穿孔法による細胞への抗原の負荷方法 |
| US7375228B2 (en) * | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| TW200424187A (en) | 2003-04-04 | 2004-11-16 | Hoffmann La Roche | New oxime derivatives and their use as pharmaceutically active agents |
| SI1611088T1 (sl) | 2003-04-07 | 2009-12-31 | Pharmacyclics Inc | Hidroksamati kot terapevtska sredstva |
| US20040220242A1 (en) | 2003-05-02 | 2004-11-04 | Leland Shapiro | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions |
| JP5416338B2 (ja) | 2003-05-09 | 2014-02-12 | デューク ユニバーシティ | Ｃｄ２０特異的抗体およびその使用方法 |
| CA2526908A1 (en) | 2003-05-21 | 2004-12-02 | Novartis Ag | Combination of histone deacetylase inhibitors with chemotherapeutic agents |
| EP1491188A1 (en) | 2003-06-25 | 2004-12-29 | G2M Cancer Drugs AG | Topical use of valproic acid for the prevention or treatment of skin disorders |
| RU2356547C2 (ru) | 2003-08-26 | 2009-05-27 | Мерк ЭйчДиЭйСи Рисерч ЛЛС | Способы лечения рака с использованием ингибиторов hdac |
| CN102349927A (zh) | 2003-08-29 | 2012-02-15 | Hdac默克研究有限责任公司 | 联合治疗癌症的方法 |
| KR20050039573A (ko) * | 2003-10-23 | 2005-04-29 | 주식회사 태평양 | 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물 |
| US20060270016A1 (en) | 2003-11-14 | 2006-11-30 | Holm Per S | Novel adenoviruses, nucleic acids that code for the same and the use of said viruses |
| US20070110719A1 (en) | 2003-11-14 | 2007-05-17 | Holm Per S | Novel use of adenoviruses and nucleic acids that code for said viruses |
| AU2003290412A1 (en) | 2003-12-30 | 2005-07-21 | Council Of Scientific And Industrial Research | Arginine hydrochloride enhances chaperone-like activity of alpha crystallin |
| GB0401876D0 (en) | 2004-01-28 | 2004-03-03 | Vereniging Het Nl Kanker I | New use for cancer antigen |
| CA2557568C (en) | 2004-02-27 | 2014-05-27 | Jane Trepel | Pharmacodynamic assays using flow cytometry |
| ES2308065T3 (es) | 2004-04-30 | 2008-12-01 | Topotarget Germany Ag | Formulacion que comprende un inhibidor de histona desacetilasa, que exhibe una liberacion bifasica. |
| WO2005112637A1 (en) * | 2004-05-14 | 2005-12-01 | Decode Chemistry, Inc. | Formulations for non-parenteral use including hydrophobic cyclodextrins |
| JP5014130B2 (ja) | 2004-08-02 | 2012-08-29 | ズィナイス オペレーションズ ピーティーワイ．エルティーディー． | Ｖｅｇｆ−ｂアンタゴニストを含む癌治療方法 |
| JPWO2006014024A1 (ja) | 2004-08-06 | 2008-05-01 | 小野薬品工業株式会社 | 精神神経系疾患治療剤 |
| MX2007001550A (es) | 2004-08-09 | 2007-04-10 | Astellas Pharma Inc | Compuestos de hidroxiamida que tienen actividad como inhibidores de histona desacetilasa (hdac). |
| US8889742B2 (en) | 2004-11-30 | 2014-11-18 | The Trustees Of The University Of Pennsylvania | Use of HDAC and/or DNMT inhibitors for treatment of ischemic injury |
| FR2879204B1 (fr) | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
| WO2006070024A2 (de) | 2004-12-31 | 2006-07-06 | Per Sonne Holm | E1 -minus adenoviren und deren verwendung |
| AU2006207325B2 (en) | 2005-01-21 | 2012-08-16 | Astex Therapeutics Limited | Pharmaceutical compounds |
| EP2522397A1 (en) | 2005-02-03 | 2012-11-14 | TopoTarget UK Limited | Combination therapies using HDAC inhibitors |
| US20060229237A1 (en) | 2005-04-07 | 2006-10-12 | Yih-Lin Chung | Treatment of gastrointestinal distress |
| GB0509225D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
| ZA200710313B (en) | 2005-05-13 | 2009-05-27 | Topotarget Uk Ltd | Pharmaceutical formulations of HDAC inhibitors |
| EP1743654A1 (en) | 2005-07-15 | 2007-01-17 | TopoTarget Germany AG | Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
| US20080292616A1 (en) | 2005-08-19 | 2008-11-27 | Government Of The United Of America, Represented By The Secretary, Department Of Health And.... | Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same |
| WO2007030567A2 (en) | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | Pparactive compounds |
| WO2007049262A1 (en) | 2005-10-27 | 2007-05-03 | Berand Limited | Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders |
| EP2361619A1 (en) | 2005-11-10 | 2011-08-31 | TopoTarget UK Limited | Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer |
| US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| AU2007217560B2 (en) | 2006-02-22 | 2012-06-28 | 4Sc Ag | Indolopyridines as Eg5 kinesin modulators |
| JP2009527534A (ja) | 2006-02-22 | 2009-07-30 | ４エスツェー アクチェンゲゼルシャフト | Ｅｇ５キネシン・モジュレータとしてのインドロピリジン |
| GB0606096D0 (en) | 2006-03-27 | 2006-05-03 | Cbmm Sa | Screening method |
| EP1839656A1 (en) | 2006-03-31 | 2007-10-03 | TopoTarget Germany AG | Use of valproic acid for the topical treatment of mild to moderate acne vulgaris |
| WO2007129062A1 (en) | 2006-05-08 | 2007-11-15 | Astex Therapeutics Limited | Pharmaceutical combinations of diazole derivatives for cancer treatment |
| EP2040731A4 (en) | 2006-06-09 | 2010-05-19 | Merrion Res Iii Ltd | SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR |
| US8338482B2 (en) | 2006-07-20 | 2012-12-25 | Wisconsin Alumni Research Foundation | Modulating notch1 signaling pathway for treating neuroendocrine tumors |
| CA2669675A1 (en) | 2006-11-10 | 2008-05-15 | Syndax Pharmaceuticals, Inc. | Combination of er.alpha.+ ligands and histone deacetylase inhibitors for the treatment of cancer |
| US8796330B2 (en) | 2006-12-19 | 2014-08-05 | Methylgene Inc. | Inhibitors of histone deacetylase and prodrugs thereof |
| WO2008090534A1 (en) | 2007-01-26 | 2008-07-31 | Berand Limited | Methods and compositions for inhibition of excessive weight gain, reduction of inappropriate eating behaviours and inhibition of binge eating for the treatment of obesity |
| US7915245B2 (en) | 2007-02-01 | 2011-03-29 | The Board Of Regents Of The University Of Texas System | Methods and compositions of trail-death receptor agonists/activators |
| WO2008101121A2 (en) | 2007-02-14 | 2008-08-21 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to promoter regulation by muc1 and klf proteins |
| WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
| EP2359828A1 (en) | 2007-06-06 | 2011-08-24 | University of Maryland, Baltimore | HDAC inhibitors and hormone targeted drugs for the treatment of cancer |
| WO2009146034A2 (en) | 2008-03-31 | 2009-12-03 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
| US20090270497A1 (en) | 2008-04-24 | 2009-10-29 | Pharmacyclics, Inc. | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors |
| WO2009137649A2 (en) | 2008-05-07 | 2009-11-12 | The Trustees Of The University Of Pennsylvania | Methods for treating thyroid cancer |
-
2006
- 2006-05-11 ZA ZA200710313A patent/ZA200710313B/xx unknown
- 2006-05-11 BR BRPI0610128-3A patent/BRPI0610128B1/pt active IP Right Grant
- 2006-05-11 JP JP2008510642A patent/JP5108750B2/ja active Active
- 2006-05-11 RS RS20120155A patent/RS52214B/sr unknown
- 2006-05-11 CA CA2606598A patent/CA2606598C/en active Active
- 2006-05-11 ES ES06727086T patent/ES2380887T3/es active Active
- 2006-05-11 EA EA201370122A patent/EA023400B1/ru not_active IP Right Cessation
- 2006-05-11 KR KR1020077029199A patent/KR101340824B1/ko active Active
- 2006-05-11 WO PCT/GB2006/001737 patent/WO2006120456A1/en not_active Ceased
- 2006-05-11 AU AU2006245495A patent/AU2006245495B2/en active Active
- 2006-05-11 US US11/913,191 patent/US8835501B2/en active Active - Reinstated
- 2006-05-11 DK DK12151966.4T patent/DK2494969T3/en active
- 2006-05-11 EP EP06727086A patent/EP1901729B1/en active Active
- 2006-05-11 CN CN2006800199663A patent/CN101189003B/zh active Active
- 2006-05-11 ES ES12151966.4T patent/ES2540204T3/es active Active
- 2006-05-11 MX MX2007013938A patent/MX2007013938A/es active IP Right Grant
- 2006-05-11 DK DK06727086.8T patent/DK1901729T3/da active
- 2006-05-11 PT PT06727086T patent/PT1901729E/pt unknown
- 2006-05-11 AT AT06727086T patent/ATE542527T1/de active
- 2006-05-11 EA EA200702467A patent/EA018982B1/ru unknown
- 2006-05-11 SI SI200631312T patent/SI1901729T1/sl unknown
- 2006-05-11 EP EP12151966.4A patent/EP2494969B1/en active Active
- 2006-05-11 HR HRP20120341TT patent/HRP20120341T1/hr unknown
- 2006-05-11 PL PL06727086T patent/PL1901729T3/pl unknown
- 2006-05-11 CN CN201210004670.1A patent/CN102579417B/zh not_active Expired - Fee Related
- 2006-05-11 KR KR1020137015868A patent/KR101329437B1/ko not_active Expired - Fee Related
- 2006-05-11 UA UAA200713711A patent/UA99810C2/ru unknown
- 2006-05-11 NZ NZ563236A patent/NZ563236A/en unknown
-
2007
- 2007-11-08 IL IL187231A patent/IL187231A/en active IP Right Grant
- 2007-12-10 NO NO20076366A patent/NO339954B1/no unknown
- 2007-12-11 EC EC2007008002A patent/ECSP078002A/es unknown
-
2012
- 2012-03-16 CY CY20121100282T patent/CY1112498T1/el unknown
- 2012-06-06 JP JP2012128900A patent/JP5567068B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-15 IL IL224229A patent/IL224229A/en not_active IP Right Cessation
-
2014
- 2014-08-05 US US14/451,928 patent/US9856211B2/en active Active
-
2017
- 2017-11-15 US US15/813,582 patent/US9957227B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008540499A5 (cg-RX-API-DMAC7.html) | ||
| JP5587198B2 (ja) | タキサン誘導体を含有する、安定性が改良された凍結乾燥医薬組成物、及びその製法 | |
| ES2899226T3 (es) | Composiciones liofilizadas en superficie específica elevada que comprende el arsénico destinadas a una administración oral en pacientes | |
| WO2001041757A1 (en) | Cyclodextrin-containing pharmaceutical composition | |
| JP5703426B2 (ja) | ヒドロキシアルキル化シクロデキストリンを含む腫瘍細胞選択的抗がん剤 | |
| BRPI0408848B1 (pt) | composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação | |
| WO2020089286A1 (en) | Cyclodextrin-based formulation of a bcl-2 inhibitor | |
| ES2901427T3 (es) | Preparación líquida parenteral que comprende un compuesto de carbamato | |
| JP6498610B2 (ja) | カバジタキセル組成物 | |
| WO2009150278A1 (es) | Una composición farmacéutica de melfalano | |
| MY150820A (en) | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance | |
| RU2443432C2 (ru) | Фармацевтическая композиция для введения инъекцией | |
| JP2010531827A (ja) | 抗腫瘍剤用ビヒクルとしてのシクロデキストリン系ナノスポンジ | |
| KR20090040299A (ko) | 특별히 표적화된 국소 투여를 위한 주사용 약제학적 조성물 | |
| WO2003099288A1 (en) | Medicinal composition | |
| JP2006519209A5 (cg-RX-API-DMAC7.html) | ||
| AU2016311704B2 (en) | Use of dihydroxyacetone in preparation of anti-cancer medicaments | |
| Rodriguez-Nunez et al. | Terlipressin continuous infusion: please mind the solvent! | |
| JP2011105796A (ja) | 抗癌剤担体用キトサン及びその製造方法 | |
| JP2015525754A5 (cg-RX-API-DMAC7.html) | ||
| JP2019504042A (ja) | 経口製剤およびその製造方法 | |
| WO2025146604A2 (en) | Method of administration of cabazitaxel compositions | |
| JP6033931B2 (ja) | 有機溶媒無含有ゲムシタビン水溶液組成物 | |
| TW201841640A (zh) | 週期素依賴型激酶7(cdk7)抑制劑之組合物 | |
| BR112019011914B1 (pt) | Formulação líquida parenteral, composição injetável, e, método para preparar uma formulação líquida parenteral |